Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study

Phase 2

• Conditions: Allergic Conjunctivitis

• Registration Number: NCT00443105
• Lead Sponsor: Assaf-Harofeh Medical Center

Brief Summary

The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2006-12
• Study First Submitted: 2007-03-02
• Study First Submitted QC: 2007-03-02
• Last Update Submitted: 2007-03-02
• Study First Posted: 2007-03-05
• Last Update Posted: 2007-03-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Subjects included if they were > 5 years old and suffered from intractable allergic conjunctivitis

Exclusion Criteria

• pregnancy or breastfeeding,history of herpetic eye disease,transplant patients concomitant administration of drugs inhibiting cytochrome CYP3A4, hypersensitivity to macrolides

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Assaf Harofeh Medical Center, Department of Ophthalmology; 🇮🇱 Zerifin, Israel